Circulating Tumour Cells, Circulating Tumour DNA and Circulating Tumour miRNA in Blood Assays in the Different Steps of Colorectal Cancer Management, a Review of the Evidence in 2019

Christou, Niki; Meyer, Jérémy; Popeskou, Sotirios Georgios; David, Valentin; Toso, Christian; Buchs, Nicolas; Liot, Émilie; Robert, Joan Lucy Béatrice; Ris, Frédéric; Mathonnet, Muriel

doi:10.1155/2019/5953036

Cited by 13 publications

(4 citation statements)

References 106 publications

(116 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A CTC is broadly defined as a cell that has escaped from a primary tumour (or a metastatic tumour site) and is identifiable in the blood circulation or lymphatic system [52]. The CTC can present itself in many different phenotypes including in a dormant state, mesenchymal or epithelial state, as a stem cell, in a cluster, or any combination of these characteristics [53]. Any cellular fragments such as tumour DNA, mRNA or a ruptured cell that has undergone apoptosis or necrosis would not meet the criteria for a CTC.…”

Section: Definition Of a Circulating Tumour Cell (Ctc)mentioning

confidence: 99%

Seeding metastases: The role and clinical utility of circulating tumour cells

Patel

Blay

2021

TUB

View full text Add to dashboard Cite

Peripheral human blood is a readily-accessible source of patient material in which circulating tumour cells (CTCs) can be found. Their isolation and characterization holds the potential to provide prognostic value for various solid cancers. Enumeration of CTCs from blood is becoming a common practice in informing prognosis and may guide therapy decisions. It is further recognized that enumeration alone does not capture perspective on the heterogeneity of tumours and varying functional abilities of the CTCs to interact with the secondary microenvironment. Characterizing the isolated CTCs further, in particular assessing their functional abilities, can track molecular changes in the disease progress. As a step towards identifying a suite of functional features of CTCs that could aid in clinical decisions, developing a CTC isolation technique based on extracellular matrix (ECM) interactions may provide a more solid foundation for isolating the cells of interest. Techniques based on size, charge, density, and single biomarkers are not sufficient as they underutilize other characteristics of cancer cells. The ability of cancer cells to interact with ECM proteins presents an opportunity to utilize their full character in capturing, and also allows assessment of the features that reveal how cells might behave at secondary sites during metastasis. This article will review some common techniques and recent advances in CTC capture technologies. It will further explore the heterogeneity of the CTC population, challenges they experience in their metastatic journey, and the advantages of utilizing an ECM-based platform for CTC capture. Lastly, we will discuss how tailored ECM approaches may present an optimal platform to capture an influential heterogeneous population of CTCs.

show abstract

Section: Definition Of a Circulating Tumour Cell (Ctc)mentioning

confidence: 99%

Seeding metastases: The role and clinical utility of circulating tumour cells

Patel

Blay

2021

TUB

View full text Add to dashboard Cite

show abstract

“…However, research on sensitive and specific CTC markers still poses numerous difficulties. Numbers of these cells in the blood of metastatic patients is insufficient for effective detection (<1 to <50 in 7.5 mL blood of a metastatic cancer patient), which motivates the search for more modern techniques of their detection, including other panels of cellular markers (apart from epithelial), typical for processes such as EMT, mesenchymal-epithelial transition (MET), with SCs traits, or in an immune evasive state [200,201]. NPs, being the subject of this review, have not yet been indicated as CTC markers.…”

Section: Role Of Circulating Tumor Cells (Ctc) In Liver Metastasismentioning

confidence: 99%

The Neuropeptide System and Colorectal Cancer Liver Metastases: Mechanisms and Management

Kasprzak

Adamek

2020

IJMS

View full text Add to dashboard Cite

Colorectal cancer (CRC), classified as the third most prevalent cancer worldwide, remains to be a clinical and research challenge. It is estimated that ~50% of CRC patients die from distant metastases, with treatment of this complication still posing significant difficulties. While liver metastasis (LM) cascade is known in the literature, its mechanisms are still unclear and remain studied in different research models. A connection is suggested between nervous system dysfunctions and a range of Neurotransmitters (Nts) (including Neuropeptides, NPs), Neurotrophins (Ntt) and their receptors (Rs) in CRC liver metastasis development. Studies on the role of NP/NP-Rs in the progression and metastasis of CRC, show the complexity of brain–tumor interactions, caused by their different forms of release to the extracellular environment (endocrine, autocrine, paracrine and neurocrine). Many stages of LM are connected to the activity of pro-inflammatory, e.g., Corticotropin-releasing Hormone Receptor 1 (CRHR1), Neuropeptide Y (NPY) and Neurotensin (NT), anti-inflammatory, e.g., Calcitonin Gene-related Peptide (CGRP), CRHR2 and Vasoactive Intestinal Polypeptide (VIP) or dual role neuropeptides, e.g., Substance P (SP). The regulation of the local immunological profile (e.g., CRH/CRHRs), dysfunctions of enteroprotective role of NPs on epithelial cells (e.g., NT/NT-R), as well as structural-functional changes in enteric nervous system innervation of the tumor are also important. More research is needed to understand the exact mechanisms of communication between the neurons and tumor cells. The knowledge on the mechanisms regulating tumor growth and different stages of metastasis, as well as effects of the action of a numerous group of Nts/NPs/Ntt as growth factors, have implications for future therapeutic strategies. To obtain the best treatment outcomes, it is important to use signaling pathways common for many NPs, as well to develop a range of broad-spectrum antagonists. This review aims to summarize the current knowledge on the importance of neuroactive molecules in the promotion of the invasion-metastasis cascade in CRC, as well as the improvements of clinical management of CRC liver metastasis.

show abstract

“…CTCs are neoplastic cells released from the primary tumor into the blood circulation and the presence of CTCs has shown to be fundamental to the cancer metastasis process 7 , 8 . Recently, enumeration of CTCs has been increasingly investigated for its potential in clinical practice such as being a criterion for selection of the first-line treatment in metastatic breast cancer 9 or biomarker for monitoring treatment in patients with metastasis colorectal cancer 10 . Additionally, the detection of CTCs in peripheral blood may influence the treatment decision at an early stage of different types of cancer, particularly in prostate cancer 11 .…”

Section: Introductionmentioning

confidence: 99%

Circulating tumor cells as a prognostic biomarker in patients with hepatocellular carcinoma

Prasoppokakorn

Buntho

Ingrungruanglert

et al. 2022

Sci Rep

View full text Add to dashboard Cite

Circulating tumor cells (CTCs) have been shown as a surrogate for cancer progression and prognostication. We aimed to determine an association between CTCs and survival of hepatocellular carcinoma (HCC) patients. Peripheral blood was obtained from 73 HCC patients to enumerate for epithelial CTCs/8 mL blood. CTCs were detected by immunoaffinity-based method using epithelial cell adhesion molecule (EpCAM) and mucin1 (MUC1). The CTCs detection rates of BCLC stages A, B, and C patients were 65.4% (17/26), 77.3% (17/22), and 96% (24/25), respectively, p = 0.018. Patients with CTCs < 5 cells/8 mL had significantly longer survival than those with CTCs ≥ 5 cells/8 mL (>36 vs. 4.6 months, p < 0.001). In multivariate analysis, CTP B, BCLC B, BCLC C, AFP ≥ 400 ng/mL, and CTC ≥ 5 cells/8 mL were independently associated with survival, with adjusted HRs (95%CI) of 4.1 (2.0–8.4), 3.5 (1.1–11.4), 4.7 (1.4–15.4), 2.4 (1.1–5.0), and 2.6 (1.2–8.4); p < 0.001, 0.036, 0.011, 0.025 and 0.012, respectively. The combination of CTCs ≥ 5 cells/8 mL and AFP ≥ 400 ng/mL provided additively increased HR to 5.3 (2.5–11.1), compared to HRs of 4.0 (2.0–8.0) and 3.5 (1.8–6.7) for CTCs ≥ 5 cells/8 mL and AFP ≥ 400 ng/mL, p < 0.001, respectively. The larger number of peripheral CTCs is correlated with higher tumor aggressive features and poorer survival of HCC patients. CTCs can potentially become novel prognostic biomarker in HCC.

show abstract

Circulating Tumour Cells, Circulating Tumour DNA and Circulating Tumour miRNA in Blood Assays in the Different Steps of Colorectal Cancer Management, a Review of the Evidence in 2019

Cited by 13 publications

References 106 publications

Seeding metastases: The role and clinical utility of circulating tumour cells

Seeding metastases: The role and clinical utility of circulating tumour cells

The Neuropeptide System and Colorectal Cancer Liver Metastases: Mechanisms and Management

Circulating tumor cells as a prognostic biomarker in patients with hepatocellular carcinoma

Contact Info

Product

Resources

About